Ionis Pharmaceuticals IncNASDAQ:IONS
- LAST PRICE38.7750
- TODAY'S CHANGE (%)0.3350 (0.8715%)
- Bid / Lots38.7500/ 1
- Ask / Lots38.7800/ 2
- Open / Previous Close38.0100 / 38.4400
- Day Range
- 52 Week Range
- Volume428,854
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IONS |
|---|---|---|
| 09:32 ET | 14160 | 37.865 |
| 09:33 ET | 655 | 38.0026 |
| 09:35 ET | 600 | 37.885 |
| 09:37 ET | 1650 | 37.5338 |
| 09:39 ET | 815 | 37.635 |
| 09:42 ET | 3400 | 37.83 |
| 09:44 ET | 3061 | 37.89 |
| 09:46 ET | 200 | 37.98 |
| 09:48 ET | 462 | 37.86 |
| 09:50 ET | 1775 | 38.015 |
| 09:51 ET | 500 | 38.05 |
| 09:53 ET | 1386 | 38.015 |
| 09:55 ET | 592 | 38.013 |
| 09:57 ET | 900 | 38.05 |
| 10:00 ET | 901 | 37.96 |
| 10:02 ET | 2618 | 37.93 |
| 10:04 ET | 4313 | 37.99 |
| 10:06 ET | 21050 | 37.97 |
| 10:08 ET | 11125 | 37.905 |
| 10:09 ET | 400 | 37.93 |
| 10:11 ET | 2600 | 37.885 |
| 10:13 ET | 363 | 37.85 |
| 10:15 ET | 1804 | 37.85 |
| 10:18 ET | 300 | 37.85 |
| 10:20 ET | 3022 | 37.83 |
| 10:22 ET | 4412 | 37.79 |
| 10:24 ET | 1218 | 37.82 |
| 10:26 ET | 2185 | 37.91 |
| 10:27 ET | 2560 | 37.895 |
| 10:29 ET | 1200 | 37.885 |
| 10:31 ET | 700 | 37.85 |
| 10:33 ET | 1872 | 37.85 |
| 10:36 ET | 769 | 37.84 |
| 10:38 ET | 200 | 37.87 |
| 10:40 ET | 1100 | 37.86 |
| 10:42 ET | 1935 | 37.94 |
| 10:44 ET | 1200 | 37.92 |
| 10:45 ET | 1500 | 37.925 |
| 10:47 ET | 3954 | 37.99 |
| 10:49 ET | 1465 | 38 |
| 10:51 ET | 3272 | 38 |
| 10:54 ET | 13146 | 38.01 |
| 10:56 ET | 3751 | 37.99 |
| 10:58 ET | 5594 | 38 |
| 11:00 ET | 27751 | 38.0148 |
| 11:02 ET | 11067 | 38.07 |
| 11:03 ET | 700 | 38.16 |
| 11:05 ET | 1385 | 38.3 |
| 11:07 ET | 1535 | 38.35 |
| 11:09 ET | 2557 | 38.29 |
| 11:12 ET | 1096 | 38.33 |
| 11:14 ET | 771 | 38.42 |
| 11:16 ET | 951 | 38.39 |
| 11:18 ET | 2319 | 38.37 |
| 11:21 ET | 300 | 38.355 |
| 11:23 ET | 1149 | 38.44 |
| 11:25 ET | 733 | 38.42 |
| 11:27 ET | 1313 | 38.53 |
| 11:30 ET | 17397 | 38.53 |
| 11:32 ET | 100 | 38.55 |
| 11:34 ET | 800 | 38.545 |
| 11:36 ET | 3982 | 38.575 |
| 11:38 ET | 1180 | 38.62 |
| 11:39 ET | 1420 | 38.63 |
| 11:41 ET | 1100 | 38.645 |
| 11:43 ET | 2463 | 38.6 |
| 11:45 ET | 1000 | 38.585 |
| 11:48 ET | 665 | 38.58 |
| 11:50 ET | 2984 | 38.62 |
| 11:52 ET | 1155 | 38.61 |
| 11:54 ET | 200 | 38.61 |
| 11:56 ET | 1217 | 38.64 |
| 11:57 ET | 1055 | 38.68 |
| 11:59 ET | 300 | 38.655 |
| 12:01 ET | 708 | 38.645 |
| 12:03 ET | 800 | 38.565 |
| 12:06 ET | 100 | 38.56 |
| 12:08 ET | 100 | 38.56 |
| 12:10 ET | 100 | 38.58 |
| 12:12 ET | 2800 | 38.56 |
| 12:14 ET | 100 | 38.55 |
| 12:15 ET | 100 | 38.555 |
| 12:17 ET | 1158 | 38.66 |
| 12:19 ET | 4224 | 38.69 |
| 12:21 ET | 1667 | 38.66 |
| 12:24 ET | 7029 | 38.7784 |
| 12:26 ET | 1796 | 38.815 |
| 12:28 ET | 459 | 38.8 |
| 12:30 ET | 1633 | 38.85 |
| 12:32 ET | 1355 | 38.855 |
| 12:33 ET | 880 | 38.82 |
| 12:35 ET | 700 | 38.815 |
| 12:37 ET | 800 | 38.75 |
| 12:39 ET | 1229 | 38.77 |
| 12:42 ET | 4536 | 38.79 |
| 12:44 ET | 900 | 38.785 |
| 12:46 ET | 1280 | 38.78 |
| 12:48 ET | 1869 | 38.7675 |
| 12:50 ET | 6047 | 38.815 |
| 12:51 ET | 3870 | 38.84 |
| 12:53 ET | 1200 | 38.865 |
| 12:55 ET | 600 | 38.82 |
| 12:57 ET | 3127 | 38.805 |
| 01:00 ET | 1613 | 38.81 |
| 01:02 ET | 1600 | 38.83 |
| 01:04 ET | 1964 | 38.8 |
| 01:06 ET | 2782 | 38.775 |
Yesterday
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE, from 9:45AM ET on Monday Nov 04, 2024 by Dow Jones
9:45AM ET on Monday Nov 04, 2024 by Dow Jones
Oct 23, 2024
Ionis to hold third quarter 2024 financial results webcast, from 7:05AM ET on Wednesday Oct 23, 2024 by Dow Jones
7:05AM ET on Wednesday Oct 23, 2024 by Dow Jones
Oct 21, 2024
Oct 9, 2024
DJ Ionis Pharmaceuticals Is Maintained at Buy by Guggenheim, from 1:25PM ET on Wednesday Oct 09, 2024 by Dow Jones
1:25PM ET on Wednesday Oct 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ionis Pharmaceuticals Inc | 6.1B | -15.3x | --- |
Tempus AI Inc | 7.6B | -5.4x | --- |
Blueprint Medicines Corp | 5.8B | -45.8x | --- |
Ultragenyx Pharmaceutical Inc | 4.7B | -7.0x | --- |
ACADIA Pharmaceuticals Inc | 2.4B | 80.6x | --- |
CRISPR Therapeutics AG | 4.3B | -15.5x | --- |
Company Information
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Contact Information
- Headquarters
- 2855 Gazelle CourtCARLSBAD, CA, United States 92010
- Phone
- 760-931-9200
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Joseph Loscalzo
- Chief Executive Officer, Director
- Brett Monia
- Chief Financial Officer, Executive Vice President - Finance
- Elizabeth Hougen
- Chief Scientific Officer
- C. Frank Bennett
- Executive Vice President, Chief Business Officer
- Joseph Baroldi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.1B |
|---|---|
Revenue (TTM) | $813.5M |
Shares Outstanding | 157.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.37 |
EPS | $-2.53 |
Book Value | $2.68 |
P/E Ratio | -15.3x |
Price/Sales (TTM) | 7.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -44.61% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
